Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5ClN2O.ClH |
| Molecular Weight | 205.041 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1=NC2=CC(Cl)=CC=C2O1
InChI
InChIKey=SFCBKXSIKZQDKX-UHFFFAOYSA-N
InChI=1S/C7H5ClN2O.ClH/c8-4-1-2-6-5(3-4)10-7(9)11-6;/h1-3H,(H2,9,10);1H
Zoxazolamine is a centrally acting muscle relaxant. It decreased striatal dopamine metabolism without affecting striatal dopamine concentrations. More specifically, Zoxazolamine was shown to decrease striatal dopamine turnover without directly affecting dopamine synthesis, catabolism, reuptake, or release. It is the IK(Ca) channel opener. It was approved for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases. Later, it was submitted for the drug's use as a uricosuric agent to treat gout. It was withdrawn from the market due to hepatotoxicity.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0042417 |
|||
Target ID: CHEMBL4305 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Flexin Approved UseZoxazolamine was indicated as a uricosuric agent to treat gout. Launch Date1956 |
|||
| Primary | Flexin Approved UseZoxazolamine was indicated for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases Launch Date1956 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13571254/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
ZOXAZOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
250 mg 4 times / day multiple, oral (starting) Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 40 years n = 1 Health Status: unhealthy Condition: chronic polyartieular gout Age Group: 40 years Sex: M Population Size: 1 Sources: |
Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (acute, 1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hepatitis | acute, 1 patient Disc. AE |
250 mg 4 times / day multiple, oral (starting) Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 40 years n = 1 Health Status: unhealthy Condition: chronic polyartieular gout Age Group: 40 years Sex: M Population Size: 1 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides. | 1974 Nov |
|
| The murine aromatic hydrocarbon responsiveness locus: a comparison of receptor levels and several inducible enzyme activities among recombinant inbred lines. | 1986 Mar |
|
| Effect of benzopyrone derivatives on drug activity and metabolism. | 1986 Oct-Dec |
|
| Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. | 2000 Mar |
|
| Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo. | 2001 Jan |
|
| Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A. | 2002 Dec |
|
| Effect of p-amino-diphenyl ethers on hepatic microsomal cytochrome P450. | 2003 Sep |
|
| Characteristics and a functional implication of Ca(2+)-activated K(+) current in mouse aortic endothelial cells. | 2004 Jan |
|
| Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. | 2005 Aug 30 |
|
| Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. | 2005 Sep-Oct |
|
| Isolation, structure elucidation and in vivo hepatoprotective potential of trans-tetracos-15-enoic acid from Indigofera tinctoria Linn. | 2006 Oct |
|
| Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice. | 2006 Oct 15 |
|
| Transcription coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PParalpha and CAR, the constitutive androstane receptor, in mouse liver. | 2007 |
|
| Alterations in xenobiotic metabolism in the long-lived Little mice. | 2007 Aug |
|
| The environmental estrogen, nonylphenol, activates the constitutive androstane receptor. | 2007 Aug |
|
| Surgical correction of fixed kyphosis. | 2007 Jun |
|
| Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution. | 2007 Jun 28 |
|
| Hepatoprotective potential of Aloe barbadensis Mill. against carbon tetrachloride induced hepatotoxicity. | 2007 May 22 |
|
| Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain. | 2008 Oct |
|
| Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. | 2008 Sep |
|
| Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). | 2009 Feb 4 |
|
| Anti-clastogenic effect of magnolol-containing Hange-koboku-to, Dai-joki-to, Goshaku-san, and Magnoliae Cortex on benzo(a)pyrene-induced clastogenicity in mice. | 2009 Jul |
|
| Inhibitory effect of magnolol on Trp-P-2-induced DNA damage in various organs in mice. | 2009 Jul |
|
| 12-(4-Chloro-phen-yl)-9,9-dimethyl-9,10-dihydro-8H-benzo[a]xanthen-11(12H)-one. | 2010 Feb 6 |
|
| Halogen, hydrogen and electrostatic interactions in 2-amino-5-chloro-1,3-benzoxazol-3-ium nitrate and 2-amino-5-chloro-1,3-benzoxazol-3-ium perchlorate. | 2010 Sep |
|
| Functional coupling of ATP-binding cassette transporter Abcb6 to cytochrome P450 expression and activity in liver. | 2015 Mar 20 |
Patents
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m11669
Created by
admin on Sat Dec 16 16:34:38 GMT 2023 , Edited by admin on Sat Dec 16 16:34:38 GMT 2023
|
PRIMARY | |||
|
5978-37-0
Created by
admin on Sat Dec 16 16:34:38 GMT 2023 , Edited by admin on Sat Dec 16 16:34:38 GMT 2023
|
PRIMARY | |||
|
17139036
Created by
admin on Sat Dec 16 16:34:38 GMT 2023 , Edited by admin on Sat Dec 16 16:34:38 GMT 2023
|
PRIMARY | |||
|
31383-41-2
Created by
admin on Sat Dec 16 16:34:38 GMT 2023 , Edited by admin on Sat Dec 16 16:34:38 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
B9H77T8HTQ
Created by
admin on Sat Dec 16 16:34:38 GMT 2023 , Edited by admin on Sat Dec 16 16:34:38 GMT 2023
|
PRIMARY | |||
|
DTXSID30589313
Created by
admin on Sat Dec 16 16:34:38 GMT 2023 , Edited by admin on Sat Dec 16 16:34:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
